| abstract |
The invention relates to a prolonged release pharmaceutical dosage form of the sustained release of an H +, K + - ATPase inhibitor, giving an extended profile plasma concentration of an H +, K + - ATPase inhibitor. The enhanced plasma profile is obtained from a pharmaceutical composition comprising a nucleus of a hydrophilic or hydrophobic matrix and an H +, K + - ATPase inhibitor and optionally pharmaceutically acceptable excipients. The dosage form can be administered once daily. |